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This study investigates the eﬀects of intermittent overnight fasting in streptozotocin-induced diabetic rats (STZ rats). Over 30
days, groups of 5-6 control or STZ rats were allowed free food access, starved overnight, or exposed to a restricted food supply
comparable to that ingested by the intermittently fasting animals. Intermittent fasting improved glucose tolerance, increased
plasma insulin, and lowered Homeostatis Model Assessment index. Caloric restriction failed to cause such beneﬁcial eﬀects. The
β-cell mass, as well as individual β-cell and islet area, was higher in intermittently fasting than in nonfasting STZ rats, whilst the
percentage of apoptotic β-cells appeared lower in the former than latter STZ rats. In the calorie-restricted STZ rats, comparable
ﬁndings were restricted to individual islet area and percentage of apoptotic cells. Hence, it is proposed that intermittent fasting
could represent a possible approach to prevent or minimize disturbances of glucose homeostasis in human subjects.
1.Introduction
Overabundant food intake with chronic positive energy
balance leads to obesity and type 2 diabetes, whilst reduction
in food intake, by increasing insulin sensitivity and improv-
ing glucose homeostasis, is currently recommended in the
treatment of these metabolic disorders [1–4]. Such a caloric
restriction may include a relative decrease of food intake [5–
7] or otherwise either a total short [8, 9] or prolonged [10]
fasting.
Intermittent overnight fasting, inspired by the daily
fasting period during the Ramadan, was recently reported
to prevent the progressive deterioration of glucose tolerance
otherwise taking place in sand rats exposed to a hypercaloric
diet [11–13]. The major aim of the present study was to
investigate whether a comparable beneﬁt of intermittent
fasting may prevail in streptozotocin-induced diabetic rats.
2.MaterialsandMethods
2.1. Streptozotocin-Induced Diabetes. Eight to 10 weeks after
birth, female Wistar rats (Charles River, Wilmington, MA,
USA) were injected intraperitoneally, after overnight starva-
tion, with streptozotocin (STZ, 65mg/kg body wt.) freshly
dissolved in a citrate buﬀer (50mM, pH 4.5). These rats were
given access during the night after the injection of strepto-
zotocin to a solution of saccharose (10g/100mL) to prevent
possible hypoglycemia. Control rats were injected with the
citrate buﬀer. Five days after the injection of streptozotocin,
the glycemia was measured with the help of glucometer
(Lifescan Benelux, Beerse, Belgium) in blood obtained from
caudal vein. Only those rats displaying a glycemia in excess
of 16.7mM were kept for further investigations.
2.2. Starvation and Restricted Food Supply. In order to
compare the eﬀects of an intermittent fasting, mimicking2 International Journal of Endocrinology
the Ramadan fasting, to that of a caloric restriction, the
experimentationinbothcontrolandSTZratswasconducted
over two successive periods. Twenty days after the injection
of either streptozotocin (STZ rats) or the citrate buﬀer
vehicle (control rats), the rats were either given free access
to food throughout the experimental period (NF: nonfasting
rats), deprived of food and water from 5 p.m. to 8 a.m.
(IF: intermittently fasting rats) or given access from 5 p.m.
onwards to an amount of food comparable to that ingested
by the IF rats (CR: calorie-restricted rats). Relative to the
food intake in NF rats, such a caloric restriction represented
a 20% decrease in food intake in the control animals and a
40% decrease of food intake in the STZ rats.
2.3. Body Weight and Food Intake. The initial body weight
was measured before the injection of streptozotocin or its
citrate buﬀer vehicle, 7 days thereafter, 20 days thereafter,
on day 4, 7, 11, 14, 18, 21, and 27 of the ﬁnal 30
days experimental period and at sacriﬁce, after overnight
starvation. Likewise, food intake was measured 15 to 20 days
(6 measurements) after injection of STZ or its vehicle in 6
control rats and 3 groups of 5-6 STZ rats, and daily (26
measurements) during the last 30 days experimental period.
2.4. Intraperitoneal Glucose Tolerance Test (IPGTT). An
IPGTT [14, 15] was conducted in all rats on day 10, 20, and
29 of the ﬁnal 30 days experimental period, after overnight
starvation. A solution of D-glucose (20%, w/v) in distilled
H2O was intraperitoneally injected in conscious rats in order
todeliver2gD-glucoseperkgbodyweight.Theglycemiawas
measured by a glucometer before and 30, 60, and 120min
after the administration of D-glucose in blood samples
obtained from a caudal vein. The total and incremental areas
under the glycemic curve (AUC) were computed in each
individual experiment.
2.5. Sacriﬁce. At the end of the experimental period, the
rats were sacriﬁced after overnight starvation and under
anesthesia provoked by the intraperitoneal injection of a
solution containing ketamine and xylocaine. Blood samples
were obtained from the heart and placed in heparinized
tubes, the plasma being then separated by centrifugation and
stored at −80◦C. The plasma D-glucose [16] and insulin
[17] concentrations were measured by methods described
in the cited references. These measurements were used to
calculate the insulinogenic index (i.e., the ratio between
the plasma insulin concentration, expressed as mU/L, and
the diﬀerence between the plasma D-glucose concentration,
expressed as mM, and 4.0mM, considered as the threshold
value for stimulation of insulin secretion by the hexose) and
the HOMA index (i.e., the product of the plasma insulin
concentration, expressed as μU/mL, times the plasma D-
glucose concentration, expressed as mM). The pancreas
were either used for the isolation of islets or ﬁxed for
immunohistochemical examination.
2.6. Insulin Secretion In Vitro. Groups of 4 islets each,
obtained by the collagenase procedure [18], were incubated
at 37◦C for 90min in 0.5mL of a salt-balanced medium
[19] containing bovine serum albumin (5mg/mL) and
equilibrated against a mixture of O2/CO2 (95/5, v/v). The
insulinreleasedbytheisletsduringincubationandtheirﬁnal
insulin content were measured by radioimmunoassay [17].
2.7. Immunohistochemical Study. For immunodetection of
insulin, pancreatic rehydrated paraﬃns e c t i o n sw e r eb l o c k e d
1h at room temperature with 1:20 normal goat serum
(Vector Laboratories, Burlingame, CA, USA) in PBS for
nonspeciﬁc reactions. The slides were incubated with pri-
mary anti-insulin (12018, Sigma-Aldrich, St Louis, MO,
USA) mouse monoclonal antibody overnight at 4◦Ca t
a concentration of 1/3000 in normal goat serum (1/20
in PBS). The secondary antibody, Rhodamine Red X-
conjugated goat anti-mouse IgG (H + L) (115-295-146,
Jackson ImmunoResearch Laboratories, West Grove, PA,
USA) was applied at a dilution of 1/200 in PBS/normal
goat serum for 30min at room temperature. The slides
were mounted, and DNA was counterstained with DAPI (In
Vitrogen, Merelbeke, Belgium). The staining patterns were
observed with an Axioplan and recorded with an Axiocam
(Carl Zeiss, Oberkochen, Germany).
2.8. β-Cell Mass Assessment. Pancreatic sections were stained
for insulin using standard ABC-DAB technique [20]. The
slides were incubated overnight at 4◦C with the ﬁrst
antibody: anti-insulin (Santa Cruz Biotechnology, Inc., CA,
USA) at dilution 1:500 in PBS with appropriate blocking
serum at a dilution of 1/20. Puriﬁed immunoglobulins (IgG)
(Sigma-Aldrich, St Louis, MO, USA) from nonimmunized
rabbit were used as negative controls. The slides were further
incubated with the secondary biotinylated antibody: goat
anti-rabbit IgG (H+L) (BA-1000, Vector Laboratories) at a
dilution of 1/300 in PBS for 30min, at room temperature.
β-cell mass was measured by point-counting morphometry
on these immunoperoxidase-stained sections [21]. The mea-
surement was performed on live using Leica Microsystems
microscope (Heerbrugg, Switzerland). A grill of 110 points
was used to assess insulin positive stained islet on each ﬁeld.
2.9. Individual β-Cell Area. Individual β-cell area was deter-
mined by using image J logician on immunoﬂuorescence
stained sections of pancreas used for β-cell apoptosis assess-
ment. The β-cell area was calculated from the ratio between
individual area and β-cell nuclei number within the area
taken in consideration.
2.10. Glucagon Immunodetection. For glucagon immunode-
tection, the same procedure as that described for insulin
immunodetectionbytheABC-DABtechnique[20]wasused.
T h es o l ed i ﬀerence consisted in the ﬁrst antibody, that is,
antiglucagon (A0565, Dako, Carpinteria, CA, USA) used at
dilution 1:400.
2.11. Apoptosis Detection. The quantiﬁcation of β-cell apop-
tosis by the TUNEL method was performed using the in
situ Cell Death Detection kit, POD (Roche Diagnostics,International Journal of Endocrinology 3
Vilvorde, Belgium). At the end of this procedure, the
pancreatic sections were rinsed with PBS and eventually
exposed overnight at 4◦C to primary anti-insulin antibody
(see above) followed by exposition for 30min at 20◦C to the
Rhodamine Red X-conjugated secondary antibody (1/200
dilution). The apoptotic index represents the ratio between
positive and total nuclei of insulin-producing cells in each
islet.
2.12. Presentation of Results. All results are presented as
mean values (±SEM), together with the number of separate
determinations (n). The statistical signiﬁcance of diﬀerences
between mean values was assessed by use of Student’s t-test.
3. Results
3.1.BodyWeight. Atdayzeroofthelast30daysexperimental
period, the mean body weights of the control and STZ rats
did not diﬀer signiﬁcantly (P>0.52) from one another,
with an overall mean value of 223 ± 4g (n = 33). Over
the 2 weeks following the injection of either streptozotocin
or the citrate buﬀer vehicle, the changes in body weight
averaged +17.6 ± 4.0g(n = 16) in control rats, as distinct
(P<0.005) from −2.0 ±5.0g(n = 17) in STZ rats. Over the
last 30 days of the experiments, the changes in body weight
failed to diﬀer signiﬁcantly, whether in the control or STZ
rats, when comparing IF animals to NF animals, with overall
mean values of +33.8 ± 2.7g(n = 10) in the control rats
and −15.9 ± 4.4g(n = 11) in the STZ rats. Expressed as a
daily change in body weight, these two mean values were not
signiﬁcantly diﬀerent (P>0.4 or more) from those recorded
in the same type of rats (control or STZ) over the 2-week
period following the injection of streptozotocin or the citrate
buﬀer vehicle. Over the last 30 days of the experiments, the
gain in body weight was much lower (P<0.04 or less) in
the CR animals than in the IF animals, with mean values of
+6.0±3.1g(n = 6) in control rats and −47.5±8.7g(n = 6)
in STZ rats (Figure 1) .Ac o m p a r a b l es i t u a t i o n( P<0.07 or
less) prevailed when considering the changes in body weight
over the entire experimental period.
3.2.FoodIntake. AsindicatedinTable 1,thefoodintakeover
thelast6daysofthecontrolperiod(day15today20afterthe
injection of STZ or its solvent), was more than twice higher
(P<0.001) in the STZ rats than in the control animals. Such
ad i ﬀerence persisted when comparing fed control and STZ
rats over the 30 days experimental period. In the IF and CR
rats examined during the last 30 days experimental period,
the food intake was again almost twice higher (P<0.001) in
STZ rats than in control animals.
The individual values considered in Table 1 represented
the mean of 6–26 measurements in each rat. During the
last 6 days of the control period, the variation coeﬃcient
(SD/mean) for the 6 successive measurements made in each
ratamountedto7.3±0.6% (n = 23) in control and STZ rats.
Likewise,overthelast30daysofthepresentexperiments,the
variation coeﬃcient for the 26 measurements made during
this period averaged 9.9 ± 0.8% (n = 5) and 9.1 ± 1.1%
(n = 5)inNFcontrolandSTZrats,respectively,ascompared
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Figure 1: Comparison between the changes in body weight over
the last 30 days experimental period in IF and CR control or
streptozotocin rats. Mean values (±SEM) refer to 5-6 individual
measurements.
Table 1: Food intake (g/day per rat).
Rats Control period
(last 6 days)a
Experimental period
(30 days)b
Control
NF 20.1 ±0.3( 5 )
IF 15.3 ±0.5( 5 )
CR 18.7 ±0.1 (6) 15.0 ±0.1( 6 )
STZ
NF 44.5 ±1.8 (5) 46.0 ±0.7( 5 )
IF 42.9 ±0.9 (6) 25.8 ±0.6( 6 )
CR 44.2 ±1.6 (6) 26.5 ±1.0( 6 )
aEach individual value represents the mean of 6 successive determinations.
bEach individual value represents the mean of 26 determinations.
(P<0.001) to 15.5 ± 0.3% (n = 5) and 16.5 ± 0.3% (n = 6)
in IF control and STZ rats.
3.3. IPGTT. The paired diﬀerence between the glycemia at
min 30 and min zero of the IPGTT was comparable (P>
0.77) in control rats (6.31 ± 0.62mM; n = 48) and STZ rats
(6.68 ± 1.15mM; n = 52).
The proﬁle of glycemia during the IPGTT conducted in
control rats is illustrated in Figure 2. The total AUC averaged
in the IF and CR control rats, respectively, 94.0 ± 3.9% (n =
16) and 96.1 ± 2.8% (n = 17) of the mean corresponding
values recorded on the same day in the fed control rats
(100.0 ± 5.0%; n = 15). None of these mean values diﬀered
signiﬁcantly from one another (P>0.35 or more). However,
as documented by the data listed in Table 2, the incremental
A U Ct e n d e dt ob el o w e ri nI Fa n dC Rc o n t r o lr a t st h a ni n
fed control rats. Thus, the values recorded in IF and CR4 International Journal of Endocrinology
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Figure 2: Glycemic proﬁle during IPGTT conducted on day 10 (left), 20 (middle), and 29 (right) of the ﬁnal experimental period in NF
(upper panels), IF (middle panels), and CR (lower panels) control rats. Mean values (±SEM) refer to 5-6 individual experiments.International Journal of Endocrinology 5
Table 2: IPGTT glycemic data in control rats.
Rats Day Time zero (mM) Total AUC (mM·min) Incremental AUC (mM·min) (n)
Control NF
10 5.12 ±0.59 1,027 ±73 412 ±120 (5)
20 5.21 ±0.27 1,177 ±121 552 ±104 (5)
29 6.44 ±0.38 998 ±104 225 ±77 (5)
Control IF
10 5.79 ±0.36 927 ±28 233 ±49 (6)
20 6.16 ±0.42 1,014 ±49 275 ±28 (5)
29 7.50 ±0.49 1,061 ±97 161 ±113 (5)
Control CR
10 6.54 ±0.32 1,081 ±34 295 ±52 (5)
20 6.21 ±0.30 1,044 ±30 299 ±42 (6)
29 6.64 ±0.74 959 ±56 160 ±75 (6)
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Figure 3: Glycemic proﬁle during IPGTT conducted in NF (a), IF (b), and CR (c) STZ rats. Mean values (±SEM) refer to 15–20 individual
experiments.
control rats, respectively, averaged 59.1 ± 15.3% (n = 16)
and 65.3 ± 9.5% (n = 17) of the mean corresponding values
recorded on the same day in the fed control rats (100.0 ±
15.1%; n = 15). Such a diﬀerence only achieved statistical
signiﬁcance (P<0.04) when comparing the overall mean
value recorded in both IF and CR rats (62.3 ± 9.5%; n = 33)
to that found in the fed control rats.
In the STZ rats, the results of the IPGTT were closely
comparablein4groupsofNFanimalsexamined20daysafter
the injection of streptozotocin or on day 10, 20, and 29 of the
ﬁnal experimental period. Hence, these results were pooled
together. Likewise, the results of the IPGTT conducted on
day 10, 20, and 29 of the ﬁnal experimental period were
pooled together in either the IF or CR STZ rats (Figure 3).
The time zero glycemia was lower (P<0.007 or less) in IF
rats than in either NF or CR rats, no signiﬁcant diﬀerence
(P>0.24) being observed between the latter two groups
of STZ rats (Table 3). Likewise, the total AUC was lower
(P<0.001) in IF rats than in either NF or CR rats, which
Table 3: IPGTT glycemic data in STZ rats.
Rats Time zero
(mM)
Total AUC
(mM·min)
Incremental
AUC
(mM·min)
(n)
NF 27.84 ±1.17 3,681 ±155 279 ±153 (20)
IF 17.97 ±1.85 2,825 ±174 668 ±149 (15)
CR 25.38 ±1.70 3,988 ±194 943 ±205 (17)
failed to diﬀer signiﬁcantly (P>0.21) from one another.
Theincrementalarea,however,wasnotsigniﬁcantlydiﬀerent
(P>0.08ormore)inIFrats,ascomparedtoeitherNForCR
rats, being only signiﬁcantly higher (P<0.02) in the CR rats
than in the NF diabetic rats.
3.4. Plasma D-Glucose, Insulin Concentrations, and Insulino-
genic and HOMA Indices at Sacriﬁce. The plasma D-glucose6 International Journal of Endocrinology
Table 4: Plasma D-glucose and insulin concentrations at sacriﬁce.
Rats Plasma D-glucose (mM) Plasma insulin (μU/mL) Insulinogenic index (mU/mmol) HOMA (mM·μu/mL)
Control
NF 8.61 ±0.88 (5) 38 ±6( 5 ) 8 .63 ±2.08 (5) 336 ±73 (5)
IF 8.12 ±1.08 (5) 32 ±2( 5 ) 9 .44 ±3.42 (5) 264 ±45 (5)
CR 7.80 ±0.72 (6) 45 ±2 (5) 14.61 ±4.51 (5) 336 ±68 (5)
STZ
NF 35.80 ±2.47 (5) 16 ±2( 5 ) 0 .48 ±0.08 (5) 548 ±57 (5)
IF 22.91 ±4.30 (6) 22 ±5( 6 ) 1 .17 ±0.51 (6) 419 ±45 (6)
CR 26.35 ±4.20 (6) 25 ±5( 6 ) 1 .16 ±0.52 (6) 592 ±129 (6)
concentration was about 3-4 times higher in STZ rats than in
control rats (Table 4). In the control rats, it was comparable
(P>0.49 or more) in NF, IF, and CR animals (Table 4). In
the STZ rats, however, the overall mean value found in the
IF and CR animals (24.63 ± 2.91; n = 12) was signiﬁcantly
lower (P<0.04) than that recorded in the NF STZ rats.
The plasma insulin concentration was about twice lower
in STZ rats than in control animals. In the latter animals, the
mean values recorded in either the IF or CR animals did not
diﬀer signiﬁcantly (P>0.26 or more) from that found in the
NF animals. Such was also the case (P>0.15 or more) in the
STZ rats.
As illustrated in Figure 4, no signiﬁcant correlation was
observed between plasma insulin and D-glucose concentra-
tion in the 15 control animals (r = +0.0416; P>0.1),
whilst a highly signiﬁcant negative correlation between these
two variables prevailed in the 17 STZ rats (r =− 0.6892;
P<0.004). Covariance analysis, however, indicated that the
two regression lines failed to diﬀer signiﬁcantly from one
another in either their slope (F = 0.567; f = 1,28; P>0.25)
or elevation (F = 2.156; f = 1,28; P>0.1).
The insulinogenic index was much higher (P<0.001)
in control rats (10.60±1.84 mU/mmol; n = 15) than in STZ
animals(0.90±0.21mU/mmol;n = 17).Ineachofthesetwo
sets of rats, no signiﬁcant diﬀerence was found between NF,
IF or CR animals. At the most, there was a trend (P<0.09)
towards a higher value for the insulinogenic index in IF and
CR diabetic rats (1.17 ± 0.34 mU/mmol; n = 12) than in the
NF STZ rats (0.48 ±0.08 mU/mmol; n = 5).
The HOMA index for insulin resistance did not diﬀer
signiﬁcantly in the 3 groups of control rats, with an overall
mean value of 312 ± 35mM·μu/mL (n = 15). Such was
also the case in the STZ rats, with an overall mean value
of 518 ± 51mM·μu/mL (n = 17) signiﬁcantly higher (P<
0.004) than that recorded in the control animals.
3.5. Pancreatic Islet Data. The release of insulin by islets
prepared from control rats and incubated for 90min at
8.3mM D-glucose averaged 87.3 ± 12.7μU/islet (n =
40). As illustrated in Figure 5, the concentration-response
relationship for insulin output at increasing concentration of
the hexose was comparable in NF, IF, and CR control rats. At
the most, there was a trend towards higher mean values in
islets prepared from IF and CR control rats as distinct from
NF control rats and incubated at 2.8mM and 8.3mM D-
glucose. However, a signiﬁcant diﬀerence between the mean
values recorded at each D-glucose concentration in each type
P
l
a
s
m
a
 
i
n
s
u
l
i
n
 
(
µ
U
/
m
L
)
60
40
20
0
02 5 5 0
Plasma D-glucose (mM)
Figure 4: Comparison between plasma insulin and D-glucose
concentrations found at sacriﬁce in control (closed circles and solid
line) and STZ (open circles and dashed line) rats. The two oblique
lines correspond to the regression lines.
of control rats (NF, IF, and CR) was only observed once
(P<0.02) among nine comparisons.
The ﬁnal insulin content of the islets prepared from
control rats failed to diﬀer signiﬁcantly after incubation at
2.8, 8.3, or 16.7mM D-glucose. Pooling all available data,
it averaged, relative to the overall mean value recorded
in each experiment after incubation at the three hexose
concentrations, 96.0 ± 5.5% (n = 39), 98.8 ± 3.8% (n =
40), and 105.0 ± 3.3% (n = 40) in islets ﬁrst exposed to
2.8, 8.3, and 16.7mM, respectively. None of these mean
values diﬀered signiﬁcantly from one another. Likewise, no
signiﬁcant diﬀerence was observed between the mean values
for the insulin content of the islets prepared from NF control
rats (347.2 ± 18.0μU/islet; n = 30) and either IF control rats
(303.0 ± 14.0μU/islet; n = 30) or CR control rats (385.1 ±
16.4μU/islet; n = 29). In a further experiment conducted
in IF control rats, the insulin content again failed to diﬀer
signiﬁcantly from that recorded in the fed control rats after
incubation at either 2.8 or 16.7mM D-glucose. Only the
mean value found in this further experiment in the islets
from IF control rats after incubation at 8.3mM happened toInternational Journal of Endocrinology 7
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Figure 5: Insulin output by islets from NF control rats (open
circles), IF control rats (closed circles), and CR control rats (open
triangles) incubated at increasing concentrations of D-glucose. All
results are expressed relative to the overall mean values recorded
at the three concentrations of the hexose in each type of rats.
Mean values (±SEM) refer to 10 (NF and CR rats) or 20 (IF rats)
separate measurements, the SEM bar ending by an arrow whenever
it exceeded the space to the next mean value. The solid line refers to
the overall mean value recorded in the three groups of rats at each
hexose concentration.
be lower (P<0.01) than that otherwise recorded under the
same experimental condition in the fed control rats.
The release of insulin (μU/islet per 90min) by islets
prepared from STZ rats averaged, at 2.8, 8.3, and 16.7mM
D-glucose, respectively, 2.08 ± 0.91 (n = 28), 4.01 ± 1.01
(n = 36), and 7.18 ± 1.70 (n = 36). It was thus signiﬁcantly
higher (P<0.02) at 16.7mM D-glucose than at 2.8mM D-
glucose. As judged from the mean values for insulin output
and content measured in each experiment, the release of
insulin represented 32.7±11.7% (n = 4), 43.0±19.4% (n =
5), and 62.6 ± 32.1% (n = 5) of the ﬁnal insulin content of
theisletsafterincubationat2.8,8.3,and16.7mMD-glucose,
respectively. The insulin content of the islets prepared from
STZ rats, expressed relative to the mean value found in each
experiment in islets ﬁrst incubated at 8.3 and 16.7mM D-
glucose (9.7 ± 1.6μU/islet; n = 70), averaged 165.5 ± 27.8%
(n = 28) after exposure to 2.8mM D-glucose, 105.1±20.1%
(n = 35) after exposure to 8.3mM D-glucose, and 94.8 ±
17.4% (n = 35) after exposure to 16.7mM D-glucose. Such
a progressive decrease in insulin content as a function of the
concentration of the hexose during incubation was validated
by the signiﬁcant diﬀerence (P<0.03) found between
the highest and lowest of these three percentages. In these
respects, no signiﬁcant diﬀerence was observed between NF,
IF and CR diabetic animals.
Both the insulin output and islet insulin content were
dramatically lower in STZ rats than in control animals. For
instance, over 90min incubation at 8.3mM D-glucose, the
mean insulin output by islets from STZ rats did not exceed
4.01 ± 1.01μU/islet (n = 36), as distinct from a mean value
of 87.3 ±12.7μU/islet (n = 40) in control animals. Likewise,
after 90min incubation at 2.8mM D-glucose, the insulin
content of the islets did not exceed 5.9±1.3μU/islet (n = 28)
in STZ rats, as distinct (P<0.001) from 331.5±20.8μU/islet
(n = 29) in control animals.
3.6. Islet Immunochemistry. The detection of insulin-
producing cells by the ABC-DAB technique yielded com-
parable images in NF, IF and CR control rats (Figures
6(a), 6(b),a n d6(c)). In the STZ rats, however, the same
technique revealed a severe decrease in insulin staining, such
a decrease being apparently most pronounced in the NF
animals(Figures6(d),6(e),and6(f)).Theimmunodetection
of glucagon-producing cells, by a comparable ABC-DAB
technique is illustrated in Figure 7. In the NF, IF, and CR
control rats, the glucagon-producing cells were typically
locatedattheperipheryoftheislets.IntheSTZrats,however,
an apparently increased number of glucagon-producing cells
seemed to invade the center of the islets.
The relative value occupied by β-cells in serial sections of
the whole pancreas did not exceed 0.20 ± 0.05% (n = 9) in
STZ rats, as compared (P<0.001) to 1.06 ± 0.07% (n = 9)
in control animals. The values recorded in the IF and CR
control rats did not diﬀer signiﬁcantly (P>0.23) from
those found in the NF control rats (Table 5). In the STZ rats,
however, both the relative and absolute values for β-cell mass
werehigher(P<0.07orless)inIFthanNFanimals,suchnot
being the case when comparing CR and NF STZ rats. When
multiplied by the weight of the pancreas measured after
5min evaporation of formol, the total β-cell mass appeared
somewhat lower in IF control rats (5.7 ±1.3mg;n = 3) than
in either NF control rats (11.1 ± 1.5mg;n = 3; P<0.05)
or CR control rats (9.6 ± 1.0mg; n = 3; P<0.08), with
an overall mean value (8.8 ± 1.0mg;n = 9) one order of
magnitude higher (P<0.001) than that recorded in the STZ
rats (1.5 ± 0.4mg;n = 9). In these experiments, the mean
pancreatic weight failed to diﬀer signiﬁcantly (P>0.66)
in control animals (0.84 ± 0.09g; n = 9) and STZ rats
(0.79 ±0.04g; n = 9). In both cases, however, and relative to
the mean values found in NF animals (100.0 ±2.8%; n = 6),
those recorded in the IF rats (68.9 ± 7.5%; n = 6) were
signiﬁcantly lower (P<0.02) than those measured in the CR
rats (99.9 ±8.0%; n = 6).
The latter data were in fair agreement with the direct
measurement of pancreas wet weight at sacriﬁce with a
paired ratio between the values obtained by direct measure-
ment at sacriﬁce and those reached after ﬁxation averaging
97.7 ± 4.2% (n = 17). Even when expressed relative to body
weight, the pancreatic wet weight at sacriﬁce represented in
the IF rats no more than 80.8 ± 5.5% (n = 6; P<0.06) of
that recorded in the CR rats (100.0 ± 6.6%; n = 7) of the
same group (control or STZ rats).
As indicated in Table 6, the individual β-cell area aver-
aged in the STZ rats 135.8 ± 5.2% (n = 60; P<0.001)
of the mean corresponding value found in control animals8 International Journal of Endocrinology
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Figure 6: Immunodetection of insulin by the ABC-DAB technique in NF (a, d), IF (b, e), and CR (c, f) control (a, b, c) and STZ (d, e, f)
rats.
(a) (b) (c)
(d) (e) (f)
Figure 7: Immunodetection of glucagon by the ABC-DAB technique in NF (a, d), IF (b, e), and CR (c, f) control (a, b, c) and STZ (d, e, f)
rats.International Journal of Endocrinology 9
Table 5: Relative and absolute values for total β-cell mass.
Rats Relative volume Pancreas weight β-cell mass
(‰) (g) (mg)
Control NF 10.76 ±0.73 (3) 1.03 ±0.06 (3) 11.12 ±1.46 (3)
Control IF 10.39 ±2.04 (3) 0.55 ±0.05 (3) 5.67 ±1.28 (3)
Control CR 10.56 ±0.70 (3) 0.92 ±0.13 (3) 9.58 ±0.95 (3)
STZ NF 1.11 ±0.08 (3) 0.81 ±0.01 (3) 0.90 ±0.06 (3)
STZ IF 3.71 ±0.88 (3) 0.68 ±0.03 (3) 2.55 ±0.64 (3)
STZ CR 1.31 ±0.55 (3) 0.88 ±0.06 (3) 1.20 ±0.57 (3)
Table 6: Individual β-cell and islet area.
Rats Sample Individual β-cell
area (μm2)
Individual islet
areas (mm2 ×103)
Control NF 1 116.2 ±3.0 (10) 23.72 ±2.67 (10)
2 102.4 ±4.5 (10) 21.49 ±1.85 (10)
Control IF 1 123.6 ±8.5 (10) 24.15 ±3.13 (10)
2 130.9 ±8.7 (10) 14.50 ±1.50 (10)
Control CR 1 119.5 ±8.3 (10) 23.30 ±2.69 (10)
2 117.3 ±6.7 (10) 24.12 ±1.61 (10)
STZ NF 1 157.1 ±25.2 (10) 1.11 ±0.23 (10)
2 131.1 ±11.9 (10) 1.57 ±0.30 (10)
STZ IF 1 192.5 ±14.0 (10) 3.34 ±0.55 (10)
2 186.4 ±12.1 (10) 5.63 ±1.18 (10)
STZ CR 1 145.4 ±8.5 (10) 5.94 ±1.13 (10)
2 156.8 ±8.4 (10) 4.20 ±1.18 (10)
(100.0±2.3%; n = 60) exposed to the same feeding schedule
(NF, IF, or CR). Whether in control rats or STZ rats, the
mean β-cell area was signiﬁcantly higher (P<0.04 or less)
in IF animals than in NF and/or CR animals. Thus, relative
to the corresponding mean value found in the NF animals
of the same group (control or STZ), that is, 100.0 ± 5.0%
(n = 40), the values recorded in CR and IF animals averaged,
respectively,107.0±3.1%(n = 40;P>0.24)and123.9±4.3%
(n = 40; P<0.001), the latter mean value being also
signiﬁcantly higher (P<0.003) than the former one.
As also documented in Table 6, the individual islet area
represented in STZ rats 14.8 ± 1.9% (n = 60; P<0.001) of
that found in the control animals (100.0 ± 4.5%; n = 60)
exposed to the same feeding schedule (NF, IF or CR). In the
control animals, such a mean islet area (expressed as mm2 ×
103) was not signiﬁcantly diﬀerent in NF rats (22.6±1.6; n =
20), IF rats (19.3 ±1.9; n = 20), and CR rats (23.7 ±1.5; n =
20). In the STZ animals, however, it increased from 1.34 ±
0.19(n = 20)intheNFratsto4.50±0.69(n = 20;P<0.001)
in the IF rats and to 5.07±0.82 (n = 20; P<0.001) in the CR
rats, the latter two mean values failing to diﬀer signiﬁcantly
(P>0.59) from one another.
Figure 8 illustrates the immunodetection of β-cells using
rhodamine-labelled secondary antibody, and Figure 9 the
immunodetection of apoptotic β-cells by the TUNEL pro-
cedure. In the control animals, the percentage of apoptotic
islet β-cells was comparable in NF, IF, and CR rats, with an
overall mean value not exceeding 4.31 ± 0.10% (n = 15), as
distinct (P<0.001) from 14.31±1.49% (n = 15) in STZ rats
(Table 7). In the latter rats, the values recorded in IF and CR
animals (11.45±0.76%; n = 10) appeared lower (P<0.004)
than that found in the NF animals (20.03 ± 2.90%; n = 5),
but the total number of β-cells examined in the NF STZ
rats (101 ± 1 cells; n = 5 )w a sm u c hl o w e r( P<0.001)
than that examined in the IF and CR rats (663 ± 62 cells;
n = 10). Incidentally, even the latter value remained much
lower (P<0.001) than the total number of β-cells examined
in the control animals (2,236 ±161 cells; n = 15).
4. Discussion
In the light of a prior study conducted in sand arts [11–13],
the major aim of the present experiments was to investigate
the potential beneﬁt of intermittent fasting in STZ-induced
diabetic rats. Parallel experiments were here conducted in
control animals.
As expected, the glycemia (or plasma D-glucose concen-
tration) and the total AUC during an IPGTT were much
higher in STZ rats than in control animals. Even the incre-
mental AUC during the IPGTT was higher (P<0.006) in
STZ rats (608 ± 105mM·min; n = 52) than in control
animals (287 ± 29mM·min; n = 48) despite a comparable
initial increment in glycemia 30min after the injection of D-
glucose. Also, as expected, the plasma insulin concentration,
the insulinogenic index, the secretion of insulin by isolated
islets, their insulin content, the relative volume occupied by
the β-cells in serial sections of the whole pancreas and the
individual islet area were much lower in STZ rats than in
control animals. Incidentally, a positive secretory response
to D-glucose was still observed in isolated pancreatic islets
from STZ rats, this coinciding with a progressive decrease
in their ﬁnal insulin content after incubation at increasing
concentrations of D-glucose. Such a decrease was not
observed, however, in pancreatic islets from control animals.
Last, the HOMA for insulin resistance and percentage of
apoptotic β-cells were also signiﬁcantly higher in STZ rats
than in control animals.
In terms of morphological ﬁndings, there was, as a rule,
little to distinguish between NF, IF, and CR control animals.
At the most, there was a trend (P<0.02) towards a
higher individual β-cell area in IF than in NF control rats.
Moreover, the pancreatic wet weight and, hence, total β-cell
mass appeared lower (P<0.04 or less) in IF control rats
than in NF control rats. A comparable situation (P<0.02)
prevailed when comparing the pancreatic wet weight in IF
STZ rats and NF STZ rats.
In the STZ rats, the major other changes attributable
to diﬀerences in feeding schedule concerned, in terms of
morphological ﬁndings, the relative and absolute values for
β-cell mass, the individual β-cell and islet area and the
percentageofapoptoticβ-cells.IntheIFSTZrats,therelative
and absolute values for β-cell mass, as well as the individual
β-cell area and islet area, were all higher than in NF STZ rats,
whilst the percentage of apoptotic cells appeared lower in IF
than NF STZ rats. In the CR STZ rats, comparable ﬁndings10 International Journal of Endocrinology
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Figure 8: Immunodetection of insulin using rhodamine-conjugated secondary antibody in NF (a, d), IF (b, e), and CR (c, f) control (a, b,
c )a n dS T Z( d ,e ,f)r a t s .
(a) (b) (c)
(d) (e) (f)
Figure 9: Detection of apoptotic β-cells by the TUNEL technique in insulin-stained pancreatic islet cells from NF (a, d), IF (b, e), and CR
( c ,f)c o n t r o l( a ,b ,c )a n dS T Z( d ,e ,f)r a t s .International Journal of Endocrinology 11
Table 7: Number and percentage of apoptotic β-cells.
Rats TUNEL plus
cell number
Total cell
number
Apoptotic
β-cells (%)
Control NF 113 ±14 (5) 2,452±325 (5) 4.65 ±0.21 (5)
Control IF 70 ±7 (5) 1,732±152 (5) 4.02 ±0.10 (5)
Control CR 107 ± 12 (5) 2,525±219 (5) 4.26 ±0.07 (5)
STZ NF 19 ±2 (5) 101 ± 17 (5) 20.03 ±2.90 (5)
STZ IF 68 ±5 (5) 643 ± 66 (5) 10.68 ±0.38 (5)
STZ CR 90 ±23 (5) 683 ±113 (5) 12.22 ±1.46 (5)
were restricted to the individual islet area and percentage of
apoptotic cells.
The much higher percentage of apoptotic β-cells in STZ
rats, as compared to control animals, is likely attributable to
two major factors. First, the β-cell cytotoxic eﬀect of STZ
should not be ignored. According to Morimoto et al. [22],
apoptosis of β-cells is already detected 6 hours after the
injection of STZ, even before the onset of hyperglycemia.
In this respect, it should be kept in mind that 3 to 14
days after STZ administration, inﬁltration of the islets by
mononuclear cells takes place, eventually resulting in the
removal of apoptotic cells by unspeciﬁc macrophages [23,
24]. Hence, the present data may well underestimate the
apoptosis index otherwise prevailing during the ﬁrst days
after STZ administration. A second factor consists of the
hyperglycemia resulting from STZ administration, since in
vitro exposure of pancreatic islets to high concentrations of
glucose also induces β-cell apoptosis [24].
The latter process may account, in part at least, for the
apparent diﬀerences between IF and CR STZ rats, in terms
of both relative β-cell mass and individual β-cell area. Thus,
accordingtothedatalistedinTables3and4,theglycemia(or
plasma D-glucose concentration) after overnight starvation,
expressed relative to the mean corresponding values found
in NF STZ rats averaged in the IF STZ rats 64.9 ± 5.7%
(n = 21), as distinct (P<0.01) from 86.6 ± 5.6% (n = 23)
in the CR STZ rats. The mean values for both the total and
incremental AUC during the IPGTT were also higher in CR
STZ rats than in IF STZ rats (Table 3). Such diﬀerences in
glucose homeostasis coincided with higher mean values for
both the relative volume of β-cells and their individual area
in IF STZ rats as distinct from CR STZ rats (Tables 5 and
6). Thus, the mean relative value of β-cells was almost twice
higher in IF than CR STZ rats, whilst the mean individual β-
cell area represented in the IF STZ rats 125.4±6.0% (n = 20;
P<0.002) of that found in CR STZ rats (100.0 ± 4.0%; n =
20). Despite the vastly diﬀerent magnitude of the IF/CR ratio
forthesetwovariables,thediﬀerencebetweenCRandIFSTZ
rats remained highly signiﬁcant (P<0.005) when pooling
together the results recorded for each of these variables.
The individual β-cell area was also always signiﬁcantly
higher in STZ rats than in control animals exposed to the
same dietary schedule (Table 6). These converging ﬁndings
concerning diﬀerences in individual β-cell area as a function
of glucose tolerance are reminiscent of the hypertrophy
of β-cells found either in vitro after exposure to a high
concentration of D-glucose [25]o rin vivo in rats which
became hyperglycemic after partial pancreatectomy [26]a n d
currently ascribed to a compensatory mechanism in residual
β-cells no more susceptible to undergo mitosis [27].
The latter consideration is not meant to deny that in
addition to β-cell hypertrophy, an increase in β-cell number,
possibly attributable to transdiﬀerentiation of glucagon-
producing to insulin-producing cells [28, 29], may partici-
pate in the diﬀerence in relative or total β-cell mass between
NF and IF STZ rats, as also suggested by the total cell
numbers listed in Table 7.
Ab e n e ﬁ c i a le ﬀect of intermittent fasting from 5p.m.
to 8a.m. in STZ rats was documented by a decrease in
glycemia at time zero of the IPGTT, a decrease in the total
glycemic AUC during the IPGTT, a lower plasma D-glucose
concentration at sacriﬁce after overnight starvation, and a
trend towards a higher plasma insulin concentration and
insulinogenic index and a lower HOMA index at sacriﬁce.
For the latter three variables, the geometric means of the rel-
evant variable (plasma insulin concentration, insulinogenic
index, and inverse of HOMA index) yielded a signiﬁcant
diﬀerence (P<0.025) between NF (100.0 ± 6.9%; n = 15)
and IF (164.4 ± 29.5%; n = 18) STZ rats. Furthermore, no
signiﬁcant adverse eﬀect of intermittent fasting (P>0.49)
was observed in terms of the changes in body weight of the
STZ rats over the 30 days ﬁnal experimental period, when
comparing NF animals (−12.4 ± 2.8g; n = 5) to IF rats
(−18.8 ±7.9g;n = 6).
Ad i ﬀerent situation prevailed in the calorie-restricted
STZ rats. No statistically signiﬁcant beneﬁcial eﬀects of
caloric restriction in the STZ rats was observed when com-
paring NF to CR diabetic animals. Moreover, the decrease in
bodyweightobservedintheSTZratsduringtheﬁnal30days
experimental period was 2.5 to 3.8 times higher (P<0.001)
in CR rats than in IF and NF animals, respectively.
Even in control rats, the gain in body weight was
much lower in CR animals than in IF ones (Figure 1). This
coincided with lower mean values for the plasma insulin
concentration, insulinogenic index, and HOMA index in IF
control rats than in CR control rats examined at sacriﬁce
after overnight starvation (Table 4). Thus, for these three
variables, the values recorded in IF control rats averaged
71.6 ± 8.6% (n = 15; P<0.06) of the mean corresponding
values found in CR control rats (100.0 ± 11.5%; n = 15).
Since such distinctions between IF and CR control rats could
not be ascribed to any diﬀerence in either food intake or
the responsiveness to D-glucose of isolated pancreatic islets
incubated in vitro, they suggest a more stressful situation in
CR control rats than in IF control animals. To a large extent,
a comparable situation may prevail in CR as distinct from IF
diabetic animals.
In conclusion, therefore, the present study allows to
extend to streptozotocin-induced diabetic rats, the proposal
that intermittent fasting exerts a beneﬁcial eﬀect on glucose
tolerance [11–13]. In our opinion, such a dietary approach
merits to be also considered as a possible approach to
prevent or minimize, if not correct, disturbances of glucose
homeostasis in human subjects.12 International Journal of Endocrinology
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